Syzygium nervosum extract reduced viability, colony formation, and cell-cycle progression in DU145 and PC-3 prostate-cancer cells at 25-400 µg/mL. Computation suggested gallic and ellagic acids may interact with AKT and CDK2, but cell and docking evidence does not establish active compounds, direct targets, safety, or efficacy in animals or humans.
Key findings
- The extract reduced viability and clonogenic growth and altered cell-cycle progression in both lines. Gallic and ellagic acids were predicted to interact with regulators including AKT and CDK2, but the abstract reports no IC50, effect size, or target validation.
Why this matters globally
The work may guide compound isolation and medicinal chemistry for resistant cancer, but crude extracts vary and culture concentrations cannot be translated directly to human dosing.
Thai researcher contribution
Walailak and Chiang Mai researchers with Nagoya City University integrated pathobiology, simulation, and pharmacognosy to screen lead compounds.
Limitations to consider
Only two cancer cell lines were used, without normal cells, organoids, animals, or patients. Extract composition and bioavailability are not standardized. Docking is predictive; no binding assay, knockdown, or rescue establishes AKT/CDK2 mechanism, so therapeutic-source claims are premature.
Verify the original sources
International Journal of Molecular SciencesRead the original article↗DOI: 10.3390/ijms27135977